Merck Pumps Pipeline With $800M Cardiome Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA-delayed vernakalant for atrial fibrillation nets handsome pact, as more-lucrative oral form awaits Phase III trials.
You may also be interested in...
Business News, In Brief
Pfizer Lays Out Primary Care Business Development Opportunities
Business News, In Brief
Pfizer Lays Out Primary Care Business Development Opportunities
Cardiome/Astellas' Kynapid Approval Seems Likely For Limited Indication, If Additional Trial Holds Up
Atrial fibrillation drug has been languishing after "approvable" letter - but approval now seems in the cards for limited indication.